Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Lee, Jae-Lyun | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Lee, Dae-Ho | - |
dc.contributor.author | Lee, Kyoo-Hyung | - |
dc.contributor.author | You, Dalsan | - |
dc.contributor.author | Jeong, In Gab | - |
dc.contributor.author | Song, Cheryn | - |
dc.contributor.author | Hong, Bumsik | - |
dc.contributor.author | Hong, Jun Hyuk | - |
dc.contributor.author | Ahn, Hanjong | - |
dc.date.available | 2020-02-28T09:43:57Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-05 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10578 | - |
dc.description.abstract | To assess the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for metastatic renal cell carcinoma (mRCC) patients and to identify predictive factors for increased progression-free survival (PFS) or overall survival (OS). The clinicopathological features, outcomes, and prognostic factors of mRCC patients who were treated with VEGFR-TKI after treatment failure using both VEGFR-TKIs and mTOR inhibitors (mTORi) were reviewed. A total of 29 eligible patients were included. Five (17 %) patients achieved partial response (PR) with a median response duration of 9.5 months (95 % CI 5.7-13.4 months), and additional 16 patients (55 %) achieved stable disease. With a median follow-up period of 19.2 months (95 % CI 18.9-19.6 months), the median PFS and OS were 3.0 months (95 % CI 1.1-4.9 months) and 4.9 months (95 % CI 2.9-6.8 months), respectively. In univariate analysis, the best response to first-line VEGFR-TKI (PR vs. non-PR, p < 0.001) and time to rechallenge (TTR, a parts per thousand currency sign12 months vs. between 12 and 24 months vs. > 24 months, p = 0.005) were identified as predictive factors for longer PFS on VEGFR-TKI rechallenge. In addition, an MSKCC risk group (intermediate- vs. poor-risk group, p = 0.027), better response at first-line VEGFR-TKI (PR vs. non-PR, p = 0.003), and TTR (a parts per thousand currency sign12 months vs. between 12 and 24 months vs. > 24 months, p = 0.026) were identified as prognostic factors for longer OS. VEGFR-TKI rechallenge may be a viable option for select metastatic RCC patients who fail both VEGFR-TKI and mTORi therapies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.subject | RANDOMIZED PHASE-3 TRIAL | - |
dc.subject | INTERFERON-ALPHA | - |
dc.subject | III TRIAL | - |
dc.subject | SORAFENIB | - |
dc.subject | SUNITINIB | - |
dc.subject | EVEROLIMUS | - |
dc.subject | DOVITINIB | - |
dc.subject | SURVIVAL | - |
dc.subject | EFFICACY | - |
dc.subject | AXITINIB | - |
dc.title | Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000354055800017 | - |
dc.identifier.doi | 10.1007/s00280-015-2725-8 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.75, no.5, pp.1025 - 1035 | - |
dc.identifier.scopusid | 2-s2.0-84938693524 | - |
dc.citation.endPage | 1035 | - |
dc.citation.startPage | 1025 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 75 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Renal cell carcinoma | - |
dc.subject.keywordAuthor | mTORi | - |
dc.subject.keywordAuthor | VEGFR-TKI | - |
dc.subject.keywordAuthor | Metastasis | - |
dc.subject.keywordAuthor | Rechallenge | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-3 TRIAL | - |
dc.subject.keywordPlus | INTERFERON-ALPHA | - |
dc.subject.keywordPlus | III TRIAL | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | EVEROLIMUS | - |
dc.subject.keywordPlus | DOVITINIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | AXITINIB | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.